⚠ Evidence note: Mechanistic aging biology translates to human interventions slowly and unreliably; model-organism lifespan gains have repeatedly failed to transfer.
Menopause and Estrogen Decline as a Primary Aging Driver
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-11-11 — The Short Peptide Elamipretide Delays Ovarian Aging in Mice: News report describes elamipretide-associated delay of ovarian aging in mice [animal-model] and improved human oocyte quality in vitro [mechanism-plausible], without establishing delayed human menopause, preserved estrogen production, or estrogen decline as a primary systemic aging driver. [animal-model] (novelty: 3)
- 2026-11-10 — Nutrition Care Strategies at the Intersection of Menopause and Obesity Pharmacotherapy.: Clinical nutrition review, no new primary data [expert-opinion]: proposes that incretin-mimetic appetite suppression and reduced nutrient intake may compound menopause-associated muscle and bone vulnerability, discussing protein optimization and targeted clinical strategies without establishing a menopause-specific drug interaction, increased sarcopenic obesity or fracture incidence, or proven prevention by these strategies. [expert-opinion] (novelty: 3)
- 2026-11-09 — The lncRNA SEPT5-GP1BB-encoded peptide ARP, upregulated by 17β-estradiol, retards HO-induced senescence of human umbilical vein endothelial cells by promoting autophagy.: [mechanism-plausible] Human endothelial cell-culture study reports estradiol-dependent induction of the SEPT5-GP1BB-encoded peptide ARP and protective autophagy, supplying a candidate downstream estrogen mechanism without testing menopause, establishing estrogen decline as a primary human aging driver, or demonstrating hormone-therapy benefit. [mechanism-plausible] (novelty: 3)
- 2026-10-12 — When Does Polyendocrine Metabolic Ovarian Syndrome (PMOS) Change Definition? A Lifespan Perspective on Menopause and Metabolic Health.: [expert-opinion] Review, no new primary data: proposes that polyendocrine metabolic ovarian syndrome (PMOS, the review’s terminology) shifts from a reproductive-age presentation to persistent cardiometabolic dysfunction after menopause, adding pre-existing endocrine-metabolic history to the menopause-aging framework without establishing accelerated human aging, estrogen loss as the primary cause, or treatment benefit. [expert-opinion] (novelty: 3)
- 2026-10-21 — Estrogen Receptor-Mediated Effects of a Phytoestrogen-Rich Soy-Based Diet on Metabolic Health Following Ovariectomy in Aged Mice.: Aged ovariectomized mouse study [animal-model]: a phytoestrogen-rich soy diet improved body composition and glucose tolerance through estrogen receptor alpha-dependent signaling, identifying a receptor-specific mediator of metabolic responses after ovarian hormone loss without establishing estrogen decline as a primary driver of aging or demonstrating benefit in postmenopausal humans. [animal-model] (novelty: 3)
- 2026-10-28 — Beyond reproduction: the emerging role of FSH in postmenopausal aging.: Review, no new primary data [expert-opinion]: proposes elevated FSH as an active contributor to postmenopausal bone loss, visceral adiposity, cardiometabolic dysfunction, and cognitive decline alongside estrogen depletion, without establishing independent human causality, validated systemic risk prediction, or clinical benefit from FSH-targeted therapy. [expert-opinion] (novelty: 3)
- 2026-10-01 — Cardiometabolic dysfunction and age at natural menopause: a prospective study.: Prospective cohort of over 2,200 South Asian women [human-observational]: baseline hypertension was independently associated with natural menopause approximately one year earlier, placing hypertension before the menopausal endpoint without establishing that it causes ovarian aging or that blood-pressure treatment delays menopause. [human-observational] (novelty: 3)
- 2026-11-01 — Life-long cardiorespiratory consequences of early life stress on estrogen actions in female rats.: Review of female-rat studies, no new primary data [expert-opinion]: synthesizes evidence that early-life stress alters estrogen-dependent neural signaling and interacts with aging and ovarian decline to exacerbate sleep apnea, hypertension, and adiposity, adding developmental history and estrogen sensitivity to the estrogen-loss framework without establishing human causality or hormone-therapy benefit. [expert-opinion] (novelty: 3)
- 2026-11-02 — Sex Hormones as Regulators of the Age- and Sex-Dependent Benefits of Caloric Restriction: An Emerging Research Protocol of a Controlled Dietary Intervention (The GendAge Weight Loss Study).: GendAge controlled-feeding study protocol tests whether age, biological sex, and postmenopausal estrogen/HRT status modify metabolic adaptation and fat loss during caloric restriction; protocol only, no outcome data, so it does not establish estrogen loss as a causal aging driver or HRT as a means to improve dietary responses [mechanism-plausible]. [mechanism-plausible] (novelty: 3)
- 2026-10-10 — Bone marrow adipose tissue in cardiometabolic disease: marrow niche remodeling, inflammatory hematopoiesis, and vascular pathology.: 2026 BMAT review notes marrow adipose expansion as an aging/cardiometabolic phenotype that intersects with postmenopausal bone loss, indirectly extending the estrogen-decline driver frame to the marrow niche — synthesis only, no sex-stratified primary data in this report. [expert-opinion] (novelty: 3)
- 2026-10-09 — Decoding the immune regulation of ovarian aging: mechanisms and therapeutic strategies.: 2026 review reframes ovarian aging and POI as immune-driven processes in which inflammaging and ovarian immune-microenvironment remodeling causally accelerate sex-steroid loss, nominating immunomodulatory strategies as candidate upstream levers on the estrogen-decline trajectory — synthesis, no new primary data. [expert-opinion] (novelty: 3)
- 2026-10-02 — Role of Menopause in Thermoregulation: Planned human trial will test whether post-menopausal estrogen loss, layered on aging, impairs thermoregulatory responses to heat stress — proposing a mechanistic account for excess heat-wave mortality in women over 65; protocol only, no results. [human-rct] (novelty: 3)
- 2026-09-30 — Sex- and age-specific patterns in bone, muscle, and fat across adulthood and their relation to osteosarcopenic adiposity phenotype: a cross-sectional study.: Cross-sectional BIA-ACC study (~9,700 adults) using LOESS mapping shows sex-specific nonlinear bone/muscle/fat/IMAT trajectories with sharper female midlife downturns around the menopausal window, and osteosarcopenic-adiposity phenotype carriers show earlier, less stable musculoskeletal decline — population-scale body-composition support for menopause as an inflection point, cross-sectional only. [human-observational] (novelty: 3)
- 2026-09-23 — Physical Activity Delays Ovarian Aging in Mice: Mouse study: treadmill training delayed ovarian aging via adiponectin signaling, and pharmacologic adiponectin receptor activation extended reproductive span — adds an exercise-adipokine input upstream of the estrogen-decline trajectory, preclinical only. [animal-model] (novelty: 3)
- 2026-09-19 — 3D-Printed and Biofabricated Scaffolds for Osteoporotic Bone Defect Repair: Mechanical Adaptation, Redox Control, Senescence Modulation and Osteoimmunomodulation.: 2026 scaffold-design review targets postmenopausal osteoporotic bone as a distinct regenerative microenvironment requiring mechanical, redox, senescence, and osteoimmune adaptation beyond healthy-bone scaffolds — indirectly extends the estrogen-decline driver frame into implant/scaffold biology, preclinical evidence only. [expert-opinion] (novelty: 3)
- 2026-09-14 — Biological age measured by DNA methylation clocks and reproductive history: Systematic review and meta-analysis.: 2026 systematic review and meta-analysis (29 studies, ~550k women) finds earlier age at menopause and higher parity cross-sectionally associated with greater epigenetic age acceleration on second-generation clocks (GrimAge, PhenoAge), while age at menarche shows no consistent link — population-scale support for menopausal timing as a female-specific aging accelerator, cross-sectional only. [human-observational] (novelty: 3)
- 2026-09-16 — Sex-specific biological aging clocks across organs and omics.: 2026 large human study constructing 38 sex-specific organ-system aging clocks across 15 organs/omics documents marked female–male divergence in genetic liability, organ proteomic networks, and disease/mortality prediction — provides population-scale, multi-organ empirical support for the sex-specific-driver framing without directly measuring estrogen or menopausal timing. [human-observational] (novelty: 4)
- 2026-09-19 — Mitochondrial Calcium Sensor Tusc2 Protects the Aging Hippocampus from Proteostasis Collapse in a Sex-Specific Manner.: Tusc2 knockout mouse study shows greater hippocampal proteostasis collapse in males than females, a male-biased vulnerability that runs opposite to the estrogen-decline framing and cautions that sex dimorphism in brain aging is not reducible to ovarian sex-steroid loss. [animal-model] (novelty: 3)
- 2026-09-15 — Dietary composition and metabolic stress differentially affect the ovarian microenvironment in mice.: Mouse study: dietary composition (Western/high-fat) drove ovarian stromal remodeling ahead of reserve loss, adding a diet–metabolic-stress input upstream of the estrogen-decline trajectory rather than direct evidence on menopause timing. [animal-model] (novelty: 3)
- 2026-07-20 — Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women: Planned trial will test whether GLP-1/GIP agonists (semaglutide, tirzepatide) improve physical function, aging biomarkers, and vascular function in postmenopausal women with obesity — extends obesity pharmacotherapy into explicit geroscience endpoints in the estrogen-deplete state; protocol only, no results. [human-rct] (novelty: 3)
- 2026-08-13 — Essentials: How to Optimize Female Hormone Health for Vitality & Longevity | Dr. Sara Gottfried: 2026 Huberman Lab Essentials episode with Sara Gottfried synthesizes decade-by-decade hormone/micronutrient tracking, cortisol/stress management, adaptive (vs chronic-cardio) exercise, and perimenopausal brain hypometabolism plus cardiometabolic risk as female-specific longevity levers — expert media recap of established guidance, no new data. [expert-opinion] (novelty: 3)
- 2026-09-05 — Vaginal estrogen: a potentially life-saving therapy: Attia (podcast/media commentary) reframes local vaginal estrogen as a longevity-relevant, potentially mortality-reducing intervention for postmenopausal GSM and recurrent UTI prevention, arguing systemic safety of the local route — expert media position on established GSM evidence, no new trial data. [expert-opinion] (novelty: 3)
- 2026-07-20 — Theca cells: active orchestrators of ovarian aging.: 2026 theca-cell review places theca-cell steroidogenic failure (impaired androgen precursor supply to granulosa aromatization) upstream of the estradiol decline that defines menopausal aging, adding a specific cellular locus to the estrogen-decline driver frame — synthesis, no new primary data. [expert-opinion] (novelty: 3)
- 2026-08-05 — Hepatic SIRT6 Deficiency Accelerates Female-Specific Aging Through SULT1E1-Mediated Estrogen Depletion.: 2026 mouse study nominates hepatic SIRT6→SULT1E1 as an upstream regulator of systemic estrogen availability: hepatocyte SIRT6 loss accelerates female-specific aging by ~17.6% lifespan reduction via SULT1E1-driven estrogen depletion, and SIRT6 activator MDL-800 restores estrogen and rescues phenotypes — adds a liver-intrinsic, non-ovarian control point over the estrogen-decline driver. [animal-model] (novelty: 3)
- 2026-08-17 — Ovarian aging and systemic health: Mechanisms and emerging intervention strategies.: 2026 review of the ovarian–systemic aging axis frames pre-menopausal ovarian decline (granulosa/oocyte cellular defects, SASP-driven local inflammaging, falling estradiol) as an upstream, sex-specific accelerator of whole-body aging, and positions ovary-targeted senolytics and hormonal/regenerative interventions as candidate levers for female healthspan — narrative synthesis, no new primary data. [expert-opinion] (novelty: 3)
- 2026-08-28 — Identifying novel druggable targets and repurposable drugs for premature ovarian insufficiency by integrated multiomics and causal inference analysis.: 2026 POI multiomics MR study surfaces granulosa-cell-intrinsic causal proteins (EPHA4, FSTL3, NUCB2) upstream of premature sex-steroid loss, offering molecular candidates for the accelerated-menopause end of the menopause-as-primary-aging-driver frame — genetic causal inference plus cell-model validation, no clinical outcome data. [human-observational] (novelty: 3)
- 2026-06-26 — Hormonal dimorphism in sarcopenia disease.: 2026 narrative review on hormonal dimorphism in sarcopenia extends the menopause-as-primary-driver frame beyond estradiol, arguing that apelin, insulin, and oxytocin axes diverge sex-specifically around the menopausal transition and jointly shape female muscle-aging trajectory — synthesis only, no new primary data. [expert-opinion] (novelty: 3)
- 2026-04-02 — Ginsenoside Rg1 enhances stem cell abundance in aging human skeletal muscle after resistance exercise.: Small randomized crossover trial in postmenopausal women: pre-exercise ginsenoside Rg1 restored circulating estradiol and raised progesterone relative to resistance exercise alone, suggesting a pharmacologic route to blunt exercise-induced sex-steroid depletion in the estrogen-deplete state — early human signal, small n. [human-rct] (novelty: 3)
- 2026-06-29 — Mechanistic redundancy and hierarchy of aging mechanisms: implications for strategies to extend healthspan and biomarker integration.: 2026 geroscience review elevates abrupt menopausal sex-hormone decline to a primary, sex-specific driver in a proposed primary/secondary/tertiary hierarchy of aging mechanisms, arguing it amplifies downstream hallmarks and warrants upstream biomarker tracking — conceptual synthesis, no new empirical data. [expert-opinion] (novelty: 3)
Open questions
Related
Contributing findings
Longer Estrogen Exposure Correlates with a Lesser Degree of Neurodegeneration
12-nov-2026
novelty 2
per-area 2
strengthens
The Short Peptide Elamipretide Delays Ovarian Aging in Mice
11-nov-2026
novelty 3
per-area 3
strengthens
Nutrition Care Strategies at the Intersection of Menopause and Obesity Pharmacotherapy.
10-nov-2026
novelty 3
per-area 3
strengthens
OsteoPreP: Food Supplements for Postmenopausal Bone Health
10-nov-2026
novelty 2
per-area 1
mentions
GLP-1-Based Therapies Across the Menopausal Transition: Dermatologic Considerations and Practical Management.
10-nov-2026
novelty 2
per-area 2
mentions
The lncRNA SEPT5-GP1BB-encoded peptide ARP, upregulated by 17β-estradiol, retards HO-induced senescence of human umbilical vein endothelial cells by promoting autophagy.
09-nov-2026
novelty 3
per-area 3
strengthens
Sex Hormones as Regulators of the Age- and Sex-Dependent Benefits of Caloric Restriction: An Emerging Research Protocol of a Controlled Dietary Intervention (The GendAge Weight Loss Study).
02-nov-2026
novelty 3
per-area 3
strengthens
Life-long cardiorespiratory consequences of early life stress on estrogen actions in female rats.
01-nov-2026
novelty 3
per-area 3
strengthens
Beyond reproduction: the emerging role of FSH in postmenopausal aging.
28-oct-2026
novelty 3
per-area 3
strengthens
Estrogen Receptor-Mediated Effects of a Phytoestrogen-Rich Soy-Based Diet on Metabolic Health Following Ovariectomy in Aged Mice.
21-oct-2026
novelty 3
per-area 3
strengthens
When Does Polyendocrine Metabolic Ovarian Syndrome (PMOS) Change Definition? A Lifespan Perspective on Menopause and Metabolic Health.
12-oct-2026
novelty 3
per-area 3
strengthens
Bone marrow adipose tissue in cardiometabolic disease: marrow niche remodeling, inflammatory hematopoiesis, and vascular pathology.
10-oct-2026
novelty 3
per-area 3
strengthens
Decoding the immune regulation of ovarian aging: mechanisms and therapeutic strategies.
09-oct-2026
novelty 3
per-area 3
strengthens
Anti-aging doctor says hormone type and combination matter in menopause treatment
06-oct-2026
novelty 2
per-area 2
mentions
Cyclooxygenase-1-sensitive oxidative responses to thromboxane-prostanoid receptor activation during vascular aging and experimental menopause.
03-oct-2026
novelty 2
per-area 2
strengthens
Role of Menopause in Thermoregulation
02-oct-2026
novelty 3
per-area 3
strengthens
Study of the Impact of Mother-of-pearl Nutritional Supplementation on the Prevention of Post-menopausal Osteoporosis
02-oct-2026
novelty 2
per-area 1
mentions
Cardiometabolic dysfunction and age at natural menopause: a prospective study.
01-oct-2026
novelty 3
per-area 3
strengthens
Brazilian Registry of Menopausal Health
01-oct-2026
novelty 2
per-area 2
mentions
Sex Hormones and Aging
30-sep-2026
novelty 2
per-area 2
mentions
Sex- and age-specific patterns in bone, muscle, and fat across adulthood and their relation to osteosarcopenic adiposity phenotype: a cross-sectional study.
30-sep-2026
novelty 3
per-area 3
strengthens
Menopause care in Brazil: policy recognition and the challenge of implementation.
25-sep-2026
novelty 2
per-area 2
mentions
Physical Activity Delays Ovarian Aging in Mice
23-sep-2026
novelty 3
per-area 3
strengthens
Cellular senescence and the SASP in skeletal ageing: convergent mechanisms of progressive bone loss in osteoporosis.
22-sep-2026
novelty 2
per-area 2
mentions
Zuogui Pill alleviates chemotherapy-induced ovarian aging and oogonial stem cell injury by modulating cGAS-STING-mediated inflammatory signaling.
19-sep-2026
novelty 2
per-area 2
strengthens
3D-Printed and Biofabricated Scaffolds for Osteoporotic Bone Defect Repair: Mechanical Adaptation, Redox Control, Senescence Modulation and Osteoimmunomodulation.
19-sep-2026
novelty 3
per-area 3
strengthens
Mitochondrial Calcium Sensor Tusc2 Protects the Aging Hippocampus from Proteostasis Collapse in a Sex-Specific Manner.
19-sep-2026
novelty 3
per-area 3
strengthens
Endocrine and Molecular Mechanisms of Oocyte Aging: From Gonadotropin Signaling to Metabolic and Microenvironmental Dysfunction.
19-sep-2026
novelty 2
per-area 2
strengthens
Sex-specific biological aging clocks across organs and omics.
16-sep-2026
novelty 4
per-area 4
strengthens
The dimorphic brain in ischemic stroke: How sex and age shape molecular pathophysiology and therapeutic responsiveness.
16-sep-2026
novelty 2
per-area 3
strengthens
Genetic Epidemiology of Ovarian Aging
15-sep-2026
novelty 2
per-area 2
strengthens
The Longitudinal Evaluation of Ovarian Aging and Cardiovascular Risk
15-sep-2026
novelty 2
per-area 3
weakens
Dietary composition and metabolic stress differentially affect the ovarian microenvironment in mice.
15-sep-2026
novelty 3
per-area 3
strengthens
Biological age measured by DNA methylation clocks and reproductive history: Systematic review and meta-analysis.
14-sep-2026
novelty 3
per-area 3
strengthens
Semaglutide in postmenopausal women: Clinical implications for weight loss, muscle health, and sleep-disordered breathing.
14-sep-2026
novelty 2
per-area 2
mentions
Overactive Bladder as a Bioenergetic Disorder: A Sex-Convergent Mitochondrial-Oxidative Framework.
14-sep-2026
novelty 2
per-area 2
mentions
Bone aging: a paradigm of multiscale degeneration and targeted rejuvenation.
14-sep-2026
novelty 2
per-area 2
mentions
Factors affecting muscle strength, muscle mass, physical performance, and sarcopenia in middle-aged menopausal women in Taiwan: A cross-sectional study.
14-sep-2026
novelty 2
per-area 2
strengthens
Bazi Bushen attenuates musculoskeletal degeneration in Ercc1mice.
10-sep-2026
novelty 3
per-area 2
strengthens
Impact of Early Aging and Menopause on the Vascular Responses to Hypoxia
10-sep-2026
novelty 2
per-area 2
mentions
Why Women Need A Different Conversation About Longevity
10-sep-2026
novelty 2
per-area 2
mentions
Improving Functioning Among Aging Women Veterans
10-sep-2026
novelty 2
per-area 2
strengthens
Cluster-derived immunometabolic profiles: association with glycemic dysregulation in elderly postmenopausal women.
09-sep-2026
novelty 2
per-area 2
mentions
Vaginal estrogen: a potentially life-saving therapy
05-sep-2026
novelty 3
per-area 3
strengthens
Identifying novel druggable targets and repurposable drugs for premature ovarian insufficiency by integrated multiomics and causal inference analysis.
28-aug-2026
novelty 3
per-area 3
strengthens
Incretin-based therapies in peri- and postmenopausal women with obesity: an expert position statement from the Spanish Menopause Society.
25-aug-2026
novelty 2
per-area 2
mentions
Inflammation, Autoimmunity and Healthy Ageing in Menopause Transition. An Observational, Cross-sectional Study
25-aug-2026
novelty 2
per-area 2
mentions
RICTOR Prevents Decidualization Disorder in Women With Advanced Maternal Age via Regulating FoxO1 Nuclear Export
21-aug-2026
novelty 2
per-area 2
mentions
hTERT Immortalization Stabilizes Human Umbilical Cord MSCs and Maintains Their Small Extracellular Vesicles With Preserved Immunomodulatory Activity and Primordial Follicle‐Activating Capacity
21-aug-2026
novelty 2
per-area 2
mentions
Ovarian aging and systemic health: Mechanisms and emerging intervention strategies.
17-aug-2026
novelty 3
per-area 3
strengthens